We recognize that patient organizations are the primary driver of rare disease research and therapy development, and that the lack of sufficient research funding for these patient organizations is a major hurdle to finding cures for rare diseases.  The 40% aims to make large, sustained research funding available for rare disease patient organizations. 

Together, we can make it happen!